+Vote!
atHome Top Story (Free subscription) | 07/22/2008
Biovail Corp. plans to reconvene its annual meeting on Aug. 8 for another vote on founder Eugene Melnyk's move to change the drug maker's board of directors and strategic direction.
+Vote!
CBC.ca (Free subscription) | 07/21/2008
Biovail Corp. said Monday it will hold a new court-ordered vote for the election of its board of directors on August 8.
+Vote!
Market Watch (Free subscription) | 07/21/2008
NEW YORK (MarketWatch) -- Biovail Corp. said Monday that it will reconvene its annual shareholders' meeting at 10 a.m. Eastern time, Aug. 8, at the InterContinental Hotel in Toronto. Its previously adjourned meeting took place June 25. The Canadian specialty pharmaceutical company said that the new date has been confirmed by an order of the Ontario Superior Court, which noted that all proxies submitted...
+Vote!
Business Wire (Free subscription) | 07/21/2008
TORONTO--(BUSINESS WIRE)--Biovail Corporation (NYSE: BVF) (TSX: BVF) today announced that it will reconvene the Company’s Annual Meeting of Shareholders at
+Vote!
atHome Top Story (Free subscription) | 07/17/2008
An Ontario court judge has ordered Biovail Corp. to reconvene its annual meeting so shareholders can vote again on whether to endorse a dissident slate of directors nominated by founder Eugene Melnyk.
+Vote!
Forbes (Free subscription) | 07/16/2008
Court rules against corporate maneuver, reopening proxy contest.
+Vote!
Forbes (Free subscription) | 07/16/2008
Court rules against corporate maneuver, reopening proxy contest.
+Vote!
atHome Top Story (Free subscription) | 07/16/2008
An Ontario court judge has ordered Biovail Corp. to reconvene its annual meeting so shareholders can vote again on whether to endorse a dissident slate of directors nominated by founder Eugene Melnyk.
+Vote!
Business Wire (Free subscription) | 07/16/2008
TORONTO--(BUSINESS WIRE)--Biovail Corporation (NYSE: BVF) (TSX: BVF) today announced that the Company will reconvene its previously adjourned Annual Meeting of Shareholders as soon as
+Vote!
Pharmalot (Free subscription) | 07/16/2008
Eugene Melnyk shoots and scores. The former Biovail ceo and founder, who owns The Ottawa Senators hockey team, was handed a victory today by a Canadian court, which ordered a new vote by Biovail shareholders, the Associated Press reports. The ruling came after Melnyk challenged procedures at the June 25 Biovail shareholders meeting at which he [...]
+Vote!
PR News Wire (Free subscription) | 07/16/2008
TORONTO, July 16 /PRNewswire/ - Eugene Melnyk and EM Holdings B.V. (The
"Concerned Shareholders") said today that they were pleased with the
decision of the Ontario Superior Court of Justice released this morning.
The Court denied the application brought by Biovail Corporation and its
CEO, William Wells, for an order validating the election of the board of
directors at the shareholder meeting convened...
1Vote!
Globe and Mail (Free subscription) | 07/09/2008
An Ontario judge will decide within the next few days whether Biovail Corp.'s June 25 annual meeting - where founder Eugene Melnyk's dissident slate of directors was rejected - will stand, or whether the company must order a new vote.
1Vote!
Business Week (Free subscription) | 07/01/2008
Analysts' opinions on stocks in the news Tuesday
+Vote!
Seeking Alpha (Free subscription) | 06/29/2008
FP Trading Desk submits: Whatever happens in court, the battle for Biovail Corp. (BVF) has almost certainly been won by the incumbent board of directors, says John Maletic, an analyst at Scotia Capital. The drug maker's annual meeting was thrown into chaos on Wednesday after founder and largest shareholder Eugene Melnyk tried to delay the meeting by withdrawing his participation. Mr. Melnyk is leading...
1Vote!
Fiercebiotech (Free subscription) | 06/26/2008
Fresh from losing an insurgent attack aimed at winning back control of Biovail, the Canadian entrepreneur says he plans to invest $50 million to $100 million of his own money to start a new R&D focused development company--Trimel Pharmaceuticals. But first he faces a looming court fight over the bitter Biovail dispute. Trimel will be a "nimble, R&D-focused pharmaceutical company" that will "capitalize...